5 Segment reporting

5 Segment reporting

The Group’s activities are in one segment, Biopharma­ceuticals.

There are no other significant classes of business, either singularly or in aggregate. The Chief Operating Decision Makers, that being the Executive Committee, review the operating results and operating plans, and make resource allocation decisions on a company-wide basis, therefore UCB operates as one segment.

Enterprise-wide disclosures about product sales, geographic areas and revenues from major customers are presented below.

5.1 Product sales information

Net Sales consist of the following:

 

 

 

€ million

2019

2018

Cimzia®

1 712

1 446

Vimpat®

1 322

1 099

Keppra® (including Keppra® XR)

770

790

Neupro®

319

321

Briviact®

221

142

Xyzal®

101

90

Zyrtec® (including Zyrtec-D®/Cirrus®)

89

101

Other products

250

323

Designated hedges reclassified to net sales

−104

100

Total net sales

4 680

4 412

 

 

 

5.2 Geographic information

The table below shows net sales in each geographic market in which customers are located:

 

 

 

€ million

2019

2018

U.S.

2 546

2 158

Japan

368

305

Germany

333

334

Europe – other (excluding Belgium)

332

331

Spain

189

179

France (including French territories)

171

163

Italy

150

149

China

139

151

U.K. and Ireland

115

131

Belgium

42

39

Other countries

399

372

Designated hedges reclassified to net sales

−104

100

Total net sales

4 680

4 412

 

 

 

The table below illustrates the property, plant and equipment in each geographic market in which the assets are located:

 

 

 

€ million

2019

2018

Belgium

337

296

Switzerland

283

295

U.K. and Ireland

65

68

U.S.

57

54

Japan

26

30

China

22

24

Germany

21

4

Other countries

29

34

Total

840

805

 

 

 

5.3 Information about major customers

UCB has 1 customer which individually accounts for more than 17% of the total net sales at the end of 2019.

In the U.S., sales to 3 wholesalers accounted for approximately 76% of U.S. sales (2018: 75%).